• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Clin Imaging . FDG PET/CT imaging features and clinical utility in COVID-19

tetano

Editor, Senior Moderator
Clin Imaging


. 2021 Aug 8;80:262-267.
doi: 10.1016/j.clinimag.2021.08.002. Online ahead of print.
FDG PET/CT imaging features and clinical utility in COVID-19


Randy Yeh[SUP] 1 [/SUP], Ahmed Elsakka[SUP] 2 [/SUP], Rick Wray[SUP] 3 [/SUP], Rocio Perez Johnston[SUP] 4 [/SUP], Natalie C Gangai[SUP] 4 [/SUP], Hooman Yarmohammadi[SUP] 5 [/SUP], Heiko Schoder[SUP] 3 [/SUP], Neeta Pandit-Taskar[SUP] 3 [/SUP]



Affiliations

Abstract

Purpose: To determine the imaging findings and potential clinical utility of FDG PET/CT in patients with laboratory-confirmed COVID-19.
Methods: We performed a single institution retrospective review of patients diagnosed with COVID-19 using real time reverse transcription-polymerase chain reaction (RT-PCR) who underwent FDG PET/CT for routine cancer care between March 1, 2020 to April 30, 2020, during the height of the pandemic in New York City, New York, United States. PET/CT scans were retrospectively reviewed for imaging findings suspicious for COVID-19. For positive scans, PET and CT findings were recorded, including location, FDG avidity (SUV[SUB]max[/SUB]) and CT morphology. Patient demographics and COVID-19 specific clinical data were collected and analyzed with respect to PET/CT scan positivity, lung SUV[SUB]max[/SUB], and time interval between PET/CT and RT-PCR.
Results: Thirty-one patients (21 males and 10 females, mean age 57 years ± 16) were evaluated. Thirteen of 31 patients had positive PET/CT scans, yielding a detection rate of 41.9%. Patients with positive scans had significantly higher rates of symptomatic COVID-19 infection (77% vs 28%, p = 0.01) and hospitalizations (46% vs. 0%, p = 0.002) compared to patients with negative scans. Eleven of 13 patients (84.6%) with positive scans had FDG-avid lung findings, with mean lung SUV[SUB]max[/SUB] of 5.36. Six of 13 patients (46.2%) had extrapulmonary findings of FDG-avid thoracic lymph nodes. The detection rate was significantly lower when the scan was performed before RT-PCR versus after RT-PCR (18.8% (n = 3/16) vs. 66.7% (n = 10/15), p = 0.009). Lung SUV[SUB]max[/SUB] was not associated with COVID-19 symptoms, severity, or disease course.
Conclusion: FDG PET/CT has limited sensitivity for detecting COVID-19 infection. However, a positive PET scan is associated with higher risk of symptomatic infection and hospitalizations, which may be helpful in predicting disease severity.

Keywords: Coronavirus disease 2019; Covid-19; FDG PET; PET/CT.
 
Back
Top Bottom